Literature DB >> 8859059

Screening for cognitive dysfunction in multiple sclerosis.

M R Basso1, S Beason-Hazen, J Lynn, K Rammohan, R A Bornstein.   

Abstract

BACKGROUND: With the use of comprehensive neuro-psychological assessments, a substantial proportion of patients with multiple sclerosis have been found to have substantial cognitive impairment. Although data generated from comprehensive examinations are useful in making recommendations for treatment interventions and compensatory strategies, the cost of such assessments prohibits their use with all patients.
OBJECTIVE: To develop a screening battery to detect cognitive impairment in patients with multiple sclerosis that is sensitive, specific, brief, and cost-effective, and could identify patients who might benefit from a more comprehensive neuropsychological examination.
DESIGN: On the basis of a comprehensive neuropsychological assessment battery, the presence of significant cognitive impairment was determined in patients with multiple sclerosis. The screening battery consisted of a subset of tests from the comprehensive battery. Performance on the screening battery was then used to predict presence of cognitive impairment on the comprehensive battery in validation and cross-validation samples. Severity of impairment on the screening battery was also regressed on ratings of functional impairment derived from the Expanded Disability Status Scale.
RESULTS: In the validation sample, the screening battery had 100% sensitivity, 80% specificity, and 88.1% overall diagnostic accuracy. In the cross-validation sample, the screening battery had 100% sensitivity, 81.8% specificity, and an overall diagnostic accuracy rate of 90.7%. chi 2 tests showed that the accuracy of the screening battery was significantly better than chance in both samples. Performance on the screening battery also predicted the level of disability ratings on the Expanded Disability Status Scale and functional systems scales.
CONCLUSIONS: The screening battery had a high degree of sensitivity, specificity, and diagnostic accuracy, while maintaining a brief administration time and high cost-effectiveness. The screening battery also predicted higher levels of disability and functional impairment as assessed by the Expanded Disability Status Scale, thereby enhancing its clinical utility. Despite its advantages, the findings do not suggest that the screening battery may be an effective substitute for a more detailed examination.

Entities:  

Mesh:

Year:  1996        PMID: 8859059     DOI: 10.1001/archneur.1996.00550100046014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  7 in total

Review 1.  [Cognitive dysfunctions in multiple sclerosis patients].

Authors:  C Engel; B Greim; U K Zettl
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 2.  Cognitive screening in multiple sclerosis.

Authors:  Peter Scherer
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

3.  Validity of the Verbal Concept Attainment Test in multiple sclerosis.

Authors:  Ryan Mulligan; Michael R Basso; Lily Lau; Bradley Reynolds; Douglas M Whiteside; Dennis Combs; Robert A Bornstein
Journal:  J Clin Exp Neuropsychol       Date:  2019-01-14       Impact factor: 2.475

Review 4.  Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

Authors:  Bridget Bagert; Patricia Camplair; Dennis Bourdette
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Neuropsychological aspects of multiple sclerosis.

Authors:  J C Brassington; N V Marsh
Journal:  Neuropsychol Rev       Date:  1998-06       Impact factor: 7.444

6.  Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery.

Authors:  Athanasios Papathanasiou; Lambros Messinis; Vasileios L Georgiou; Panagiotis Papathanasopoulos
Journal:  ISRN Neurol       Date:  2014-03-13

7.  P300 wave changes in patients with multiple sclerosis.

Authors:  Nikolina Ivica; Marina Titlic; Sanda Pavelin
Journal:  Acta Inform Med       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.